Purpose: This study evaluated the cost-effectiveness of first-line treatments of relapsing-remitting multiple sclerosis (RRMS) (dimethyl fumarate [DMF] 240 mg PO BID, teriflunomide 14 mg once daily, glatiramer acetate 20 mg SC once daily, interferon [IFN]-β1a 44 mg TIW, IFN-β1b 250 mg EOD, and IFN-β1a 30 mg IM QW) and best supportive care (BSC) in the health care payer setting in Finland.
Findings: Based on the modeled results, teriflunomide was less costly, with greater QALYs, versus glatiramer acetate and the IFNs. Teriflunomide had the lowest ICER (24,081) versus BSC. DMF brought marginally more QALYs (0.089) than did teriflunomide, with greater costs over the 15 years. The ICER for DMF versus teriflunomide was 75,431. Teriflunomide had 450% cost-effectiveness probabilities with a willingness-to-pay threshold of o€77,416/QALY gained. According to BTR, teriflunomide was first-best among the disease-modifying therapies, with potential willingness-to-pay thresholds of up to €68,000/QALY gained. In the IIA, teriflunomide was associated with the longest incremental quality-adjusted survival and time without cane use. Generally, primary outcomes results were robust, based on the sensitivity analyses. The results were sensitive only to large changes in analysis perspective or mixed-treatment comparison.
Implications: The results were sensitive only to large changes in analysis perspective or MTC. Based on the analyses, teriflunomide was cost-effective versus BSC or DMF with the common threshold values, was dominant versus other first-line RRMS treatments, and provided the greatest impact on investment. Teriflunomide is potentially the most cost-effective option among first-line treatments of 
INTRODUCTION
Multiple sclerosis (MS)-a chronic progressive, autoimmune, inflammatory disease-affects 42 million people worldwide. Approximately 89% of cases are classified as relapsing-remitting MS (RRMS) at the time of diagnosis. 1 MS prevalence is particularly high in the United Kingdom, the United States, Canada, Germany, and Scandinavia. 2, 3 In Finland, MS prevalence varies regionally, from 100 to 200 per 100,000 inhabitants. [4] [5] [6] [7] In young adults with MS, prognosis is based on an individual's factors. 1 The progression and accumulating disability cause a significant human and economic burden [8] [9] [10] [11] [12] [13] [14] [15] and the need for support. 16 The risk for death among Finnish patients with MS is 2.8-fold compared with that in the general population, being 3.4-fold in women and 2.2-fold in men as early as 2 to 10 years after diagnosis. 17 Relapse, MS progression, and disability level (eg, higher Expanded Disability Status Scale [EDSS] score 18 ) are associated with a higher risk for mortality, 17, 19, 20 additional costs, [9] [10] [11] [12] [13] [14] and quality of life (QoL) losses. 9, 10, 12, 14, [21] [22] [23] [24] MS treatment with disease-modifying therapies (DMTs) is aimed at decreasing the inflammatory activity leading to relapses, stopping or slowing progression of residual disability, and, eventually, delaying the progression to the secondary progressive phase. However, long-term prognosis among treated patients is largely unknown. Based on Finnish drug reimbursement and sales data, 25 commonly used first- We evaluated the cost-utility of injectable and oral first-line DMTs in the Finnish population of patients with RRMS, based on a decision-analytical model. To our knowledge, there are no previously published journal articles on the cost-utility of first-line oral DMTs in a European setting or on oral and injectable DMTs for first-line treatment of RRMS. In addition, progression of RRMS in Finnish patients has not been assessed before, and the 4 different approaches elaborating the key results from MS cost-utility analysis have not been previously reported.
MATERIALS AND METHODS
The cost-utility of the first-line DMTs in the Finnish RRMS population was assessed in a decisionanalytical modeling framework 38 by implementing a Markov cohort model with mutually exclusive health states in Excel 2007, including Visual Basic for Applications (Microsoft Corporation, Redmond, Washington). The modeling approach followed the Finnish guidance for health economic analyses.
39
The primary outcome of analysis was the modeled incremental cost-effectiveness ratio (ICER), reported as Euros per quality-adjusted life-year (€/QALY) gained. The interpretation of ICER is challenging in Finland because the decision maker's willingness-topay (WTP) threshold per QALY gained has not been publicly declared, 40 and significant variation in
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decision maker WTP between diseases may exist. 41 Based on our experience, the UK thresholds 42, 43 could be applicable in Finland, so that values of o$ €25,000 or €25,000-37,000/QALY gained would indicate most plausible or plausible cost-effectiveness, respectively; and, on average, €55,000/ QALY gained could be acceptable for end-of-life treatment based on the UK population-weighted decisions. This applicability of UK thresholds is based on the observation that many articles from Finland 41,44-55 have referred to a WTP threshold of $ €50,000/QALY gained, which is probably based on the so-called "dialysis argument." 41 The Finnish
Medicines Agency has considered that €68,000/QALY gained approaches the maximum cost-effectiveness threshold for a life-threatening cancer 56 -a result well in line with earlier Finnish average findings.
41
The health care payer setting, which is recommended in the Finnish guidance for health economic analyses, 39 was used in the modeling. This model includes direct health and social care costs, and excludes income transfers (taxes) and indirect costs (eg, time costs, disability payments, presenteeism, absenteeism, and informal care). A scenario analysis, including productivity losses, 14 was performed to assess the robustness of this direct-costing perspective. A summary of the modeled key research questions is given in Table I as an extended PICO framework, which is used to capture and clarify the essential parts of complicated cost-effectiveness assessment in a sensible order (namely, PICOSTEPS: P, patients; I, interventions; C, comparator; O, outcomes; S, setting; T, time horizon; E, effects; P, perspective; and S, sensitivity analyses). A relatively straightforward, limited cost-benefit analysis (clinical value analysis) approach was recently developed. 46 As a secondary complementary analysis, an impact investment assessment (IIA) was carried out to increase the clinical appeal and interpretation of the primary outcome results. 46 The IIA here covered a fixed drug-related budget based on the most affordable DMT and incremental quality-adjusted survival or time to cane use (EDSS score, 6) versus best supportive care (BSC; trial comparator). The outcome (impact on investment [II]) of the IIA was the duration of benefit obtained in comparison with BSC with the fixed budget. This IIA incorporated an explicit minimal willingness-to-invest (WTI) value for DMT based on the most affordable DMT and, thus, demonstrated the mean absolute cost-benefit in terms of a single unit:
where i indicates a particular drug treatment. Consequently, the result of the IIA is a standardized benefit (II) obtained with the given WTI (in fact, the WTI can be greater than the minimum assumed here, and the benefit increases accordingly).
Patients
Finland's MS research registry data were used to define the cohort characteristics in the model. Based on the MS research registry data (713 ambulatory patients from Finland, with MS diagnosed in 1991-2010 and an EDSS score of 0-6.5 observed at baseline; see Supplemental Material A in the online version at http://dx.doi.org/10.1016/j.clinthera.2017.01.028), the mean age of modeled patients was 35.64 years, and the female/male ratio was 2.57. The distribution of EDSS scores at baseline is shown in Figure 1 .
Model
The clinical course of MS was modeled ( Figure 2) 73,74 to capture all relevant evidence, 38, 39, 43 as no direct comparison is currently available. Models are always hypothetical and contain an element of uncertainty, but when relying on conservative and fair structure and estimates-and keeping the modeling assumptions in mind-they can produce useful information for decision making.
In the model shown in Figure 2 , patients with RRMS either maintained the same EDSS or transited to another EDSS health state as the disease progressed, developed secondary progressive MS (SPMS), transited to another EDSS state in SPMS, or died (EDSS score, 10; absorbing state) within the 1-year model cycles. Within each cycle, patients experienced a relapse (with/without hospitalization) and/or an adverse event (AE). The relative effects of DMTs were implemented as modifiers of the modeled clinical course of MS. Midcycle estimates (life-table method  of half-cycle correction 75-77 ) were used to avoid overor underestimation of modeled outcomes.
Disease Progression
Disease progression and relapses were modeled independently. Disease progression in terms of the EDSS score development during RRMS was estimated from Finland's MS research registry data, consisting of 2299 EDSS measurements. The probability of transiting from RRMS to SPMS was estimated, and EDSS development during SPMS was based on results 59 The relapse rates in patients not receiving DMTs were taken from published references. 21, 60 The percentage of relapses leading to hospitalization (30.7%) was estimated from the TEMSO trial.
30,32,33
The annual probability of death was modeled based on Finland's general population mortality rates by applying the observed MS female/male ratio of 2.57 from Finland's MS research registry data to Finland's all-cause age-and sex-specific mortality rates from the year 2014, 61 multiplying the sexweighted general population mortality rate by the EDSS-specific standardized mortality ratio, and converting the result to give the probability. 
Quality-adjusted Survival
The EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) QoL for EDSS scores was modeled on the basis of data from DEFENSE (Burden of Illness in Multiple Sclerosis), 14 Findings from studies suggest greater disutility for relapse with hospitalization compared with relapses without hospitalization. 23, 24 In a US study, the QoL losses in relapsed patients with and without hospitalization were reported as -0.302 and -0.091, respectively. 24 The latter estimate is similar to the Finnish relapse loss, that is, -0.064, 14 which used an extensive 1-year recall period and did not make a distinction between hospitalized and nonhospitalized patients or number of relapses.
To approximate the QoL loss associated with hospitalizations, the Finnish QoL loss was weighted with the observed ratio between the QoL losses for hospitalized and nonhospitalized relapses in the US study 24 (ratio -0.302/-0.091 ¼ 3.3187) to obtain disutility for hospitalized patients in Finland. The applied QoL losses in relapsed patients with and without hospitalization in the model were -0.212 and -0.064, respectively. The QoL effect of relapse was assumed to last for 3 months. 23 
Costs
Annual DMT cost was calculated using the indicated mean dose of each drug and number of doses per year (365.25 d/y), determined for each treatment regimen based on the product labeling. For drugs with multiple package sizes, the drug costs were estimated by weighting of the package costs by their estimated market share (Table II) . A 100% dose intensity and adherence were assumed.
Administration, monitoring ( In a scenario analysis, the relationship between EDSS and annual direct care costs (excluding DMT costs) was estimated based on a nonlinear interpolation of findings reported in a study from Finland, 13 as follows:
Annual direct ðDMTs excl:Þ costs ¼€ð128:44 Ã EDSS 2 þ 4266:60 Ã EDSS-2480:10Þ;
converted to 2014 real value 71 and with EDSS 0 set to €0. The costs applied in this sensitivity analysis were well in line with those from other MS cost studies from Finland 15 and elsewhere.
Sensitivity and Generalizability of Results
The robustness and generalizability of the base case results were assessed using various deterministic and probabilistic sensitivity analyses (DSA and PSA, respectively). The base case was based on most credible inputs. DSAs were based on 25 different scenarios, including major or noncredible changes in methods, health risks, treatment, costs, QoL, population, and settings. Means based on all 25 DSA scenarios were also calculated. The details of the DSAs are shown in Table IV .
Probabilistic Sensitivity Analysis
For PSA, a second-order Monte Carlo simulation was used to take into account the joint variation in the economic and clinical outcomes due to sampling uncertainty related to model parameters. The following distributions were used: β for ARR and withdrawal rates, γ for EDSS-related and treatment costs, log-normal for EDSS transitions, disease progression hazard rates, treatment effect on ARR, treatment effect on hospitalization relapse percentage and QoL, and Dirichlet distribution for the percentage of relapses involving hospitalization (see Supplemental Material C in the online version at http://dx.doi.org/ 10.1016/j.clinthera.2017.01.028). Based on the PSA, cost-effectiveness acceptability frontiers demonstrated optimal treatment to maximize net benefit with different WTP thresholds, and Bayesian treatment ranking ranked the best treatments.
RESULTS
The average modeled base case results are reported in Table V . The mean projected 15-year total payer's direct costs differed considerably (by 17.2%) between the most affordable (teriflunomide) and the most costly (IFN-β1b SC) DMT. The respective relative QALY gain difference was 9.3%. The maximum relative QALY difference was 10.6% between the 2 DMTs (DMF and IFN-β1b SC).
The modeled key outcome (ICERs €/QALY gained in comparison with BSC alone) ranged considerably, from Figure 3 ). If the WTP threshold for additional QALY gained is set to the most plausible level (€25,000), only teriflunomide represents a cost-effective alternative to BSC alone, based on the modeling. If the WTP is between €37,000 (plausible) and €55,000 (end of life) per QALY gained, only teriflunomide and DMF represent cost-effective alternatives to BSC alone. However, with a modeled ICER of 75,414 for DMF versus teriflunomide, DMF is unlikely to be considered cost-effective in the Finnish setting given the unofficial assumed WTP thresholds detailed in Materials and Methods.
The cost-benefit analysis type IIA utilized the minimal mean expected DMT-related discounted (Table VI) show that the ranking of DMTs in terms of incremental cost-effectiveness appears to be generally robust for sensible changes in modeling assumptions or input variables. The results were sensitive to large changes in the modeled perspective or mixed treatment comparison. As the base case was performed on the basis of a representative population in Finland with characteristics well in line with the indication for teriflunomide, TEMSO trial results on patients' characteristics and transition probabilities in the placebo group were used in the subgroup analysis. Based on the analysis, the results are also generalizable to an older and more disabled population. Among the 25 modeled DSA scenarios, teriflunomide versus BSC was cost-effective in 72%, 84%, 96%, and 96% of scenarios with WTPs of €25,000, €37,000, €55,000, and €68,000/QALY gained, respectively. DMF versus teriflunomide was cost-effective in 0%, 0%, 4%, and 28% of the 25 DSA scenarios at these respective WTPs. AEs, adverse events; BSC = best supportive care; DMF = dimethyl fumarate; Dom. = dominated; GA = glatiramer acetate; ICER = incremental cost-effectiveness ratio; ICUR = incremental cost-utility ratio; IFN = interferon; QALY = quality-adjusted life-year.
For the results of the modeled PSA, see Supplemental Material C in the online version at http://dx.doi.org/10.1016/j.clinthera.2017.01.028. In summary, the PSA results were in line with the deterministic results-teriflunomide dominated injectable first-line DMTs, and DMF had a high mean ICER of 76,803 (2.5%-97.5% percentile, 52,105-139,595; 96% and 75% of ICERs exceeded 55,000 and 68,000, respectively) versus teriflunomide. Teriflunomide had 450% cost-effectiveness probabilities at WTPs of o€77,416/QALY gained versus other first-line DMTs. According to the Bayesian treatment ranking, teriflunomide was the first-best among the DMTs with all unofficial WTP thresholds from Finland mentioned earlier.
DISCUSSION
The findings from this modeling study of first-line DMTs for RRMS over 15 years suggest that teriflunomide 14 mg saves costs in comparison with all other reimbursed first-line DMTs in Finland; is costeffective in comparison with DMF 240 mg at the cited threshold values; dominates injectable first-line DMTs; and, as a complementary result, is associated with the most value gained versus BSC as per the limited DMT-related budget (WTI). In some earlier cost-utility analyses of first-line DMTs for RRMS, [87] [88] [89] [90] [91] DMTs in comparison with BSC have been found not to be cost-effective based on the commonly cited threshold values-the situation was similar with GA, IFN-β1a IM, and IFN-β1b SC. These outcomes were largely explained by drug prices and clinical parts of the analysis, that is, short-term efficacy and tolerability and long-term efficacy and persistence of treatments.
The findings from the cost-benefit analysis type IIA based on the WTI seemed to follow the primary outcomes, yet a clear distinction on modeled II for teriflunomide versus BSC in comparison with other DMTs versus BSC was demonstrated with the assumed minimal DMT-related WTI of €42,077/patient. The IIA developed recently is a clinical value-assessment method that could increase clinical interpretation and appeal of the results, and indicate best IIs. However, based on the findings from Soini et al, 46 IIA cannot fully substitute the primary cost-effectiveness analysis outcomes if it ignores everything other than drug costs, differences in QoL, differences in AEs, and discounts and mixes the time horizons (ie, costs and benefits are gained from different timelines). Thus, IIA can easily result in investment biases and partial optimization of limited budgets. IIA, as such, probably should not be used as a primary method without acknowledging its limitations-here, the objective of the IIA was only to elaborate and complement the primary outcome based on a clear DMT-related cost and DMT-related II approach. In this study, the IIA was based on a modeling approach capable of synthesizing all of the known evidence. Comprehensive methods and data were needed for a valid IIA. In addition to modeling methods, data validity and generalizability can be an issue in decision-analytical modeling. For example, the DEFENSE survey 14 is the most comprehensive, recent, and up-to-date assessment of the MS burden in Finland. However, the results from DEFENSE, as such, should be interpreted with caution. There are various reasons for this: the DEFENSE setting was cross-sectional, with varying patient recall (ie, recall bias can be an issue and there was no link between the cost outcomes and varying recall time, eg, relapses and EDSS-related costs); the base population was limited to active Finnish Neuro Society members, with only 36.9% of invited members participating in the survey (ie, about 10% of the Finnish Neuro Society); EDSS was self-assessed and official indexes based on national statistics. 71, 85 In some countries, such information does not exist. Currently, Finland is undergoing health care, social welfare, and regional government reform, 116 which is likely to result in digitized service solutions for the primary (eg, benchmarking service producers) and secondary (eg, market access to new drugs and devices) uses of national, areal, local, and biobank health care and social welfare data in terms of effectiveness and cost-effectiveness. 117 Furthermore, the Finnish parliament recently received a proposal for a risk-sharing scheme centered around an agreement-based conditional reimbursement from the government of Finland. However, the official wholesale price in the application would still need to be affordable, and the risk-sharing scheme would be available only through the optional application process. 118, 119 This development has the potential to further increase the efficiency of Finland's health care system and the relevance of modeling-based health economic assessments. Finally, Finland's guidance for health economic analyses 39 is well in line with many other cost-effectiveness analysis guidelines.
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Health economic modeling is needed to handle the multidimensional assessment challenge, to summarize the trial evidence and local input data, to enable extrapolations and discounting, and to produce results in terms of generalizable outcomes with standard interpretation. In the future, it will be necessary to assess the effects of the risk-sharing scheme with some treatments. Thus, by necessity, health economic models are simplifications of a very complicated reality. Here, these assumptions are discussed.
In the model, potential treatment sequences were excluded, and switching between different DMTs was not accounted for. However, dropping out of first-line DMT altogether was included. To analyze the costutility of first-line RRMS DMTs, a sequential approach was not needed. A sequential approach would be more viable in later treatment line assessment or in health technology assessment searching for the optimal treatment sequence. Furthermore, there was no gold standard treatment sequence based on Finnish data, and the treatment of patients with RRMS seemed to be guided by per-patient decisions (which are probably affected by disease severity, disease progression, patient/clinician preferences, and potential DMT-related AEs).
In the selected modeling approach, all DMTs compared were handled equally by assuming similar treatment after the first-line DMT, and the result was not jeopardized by inherent and potentially problematic assumptions related to second-and later-line DMT efficacy, tolerability, and washout. Furthermore, in a sequential model, the result may be confounded by potential population changes between the treatment lines. In the present analysis, the results were directly related to differences due to the first-line DMT. In the evaluation, the first-line DMTs were being compared against each other, which potentially was associated with less uncertainty and fewer assumptions, and also in reduced bias and confounding in comparison with a sequential approach relying on multiple additional assumptions due to lack of data. Furthermore, all of the DMTs in the comparison were pharmacy prescription drugs, which overcomes issues of comparing intravenously administered hospital drugs (eg, further-line or high-activity MS treatments) and pharmacy prescription drugs 44, 47 and are currently subject to public reimbursement in Finland.
In earlier cost-effectiveness analyses of treatments for diseases other than MS, if the treatment sequence Clinical Therapeutics included treatment options that were not the most cost-effective, the incremental cost-effectiveness of the sequence deteriorated in comparison with base treatments. 45, 48, 129, 130 First-line MS DMTs lacked published cost-utility evidence; thus, there are no supporting publications to benchmark or determine the optimal MS treatment sequence. Furthermore, in these situations, it was more important to know how DMTs perform in comparison with the minimum case (BSC). Based on the Finnish MS research registry data, only a percentage of patients with RRMS are currently actively treated. This may be for reasons connected with efficacy, tolerability, the patient, or the clinician.
Based on the Finnish MS research registry data, MS DMT-related AEs seem to accumulate in some patients. However, owing to the similarity of some AEs produced by frequently used first-line MS injectable DMTs, it is uncertain whether AEs occur in some patients after changing from one first-line DMT to another. Furthermore, no well-controlled research evidence exists demonstrating the clinical gains or benefits of switching the first-line DMT.
EDSS transitions in this modeled evaluation were based on data from Finland (RRMS) and London, Ontario, Canada (SPMS), 59 135 The effects of RRMS EDSS transitions were tested in sensitivity analyses, and the relative results remained unchanged. In fact, the recently published RRMS transitions from British Columbia, Canada 57 agree with those from Finland.
Last, in addition to clinical real-world evidence, future real-world studies should collect real-world data to support modeled economic evaluations. They should, accordingly, include comprehensive assessments of the EDSS specified separately for RRMS; SPMS and primary progressive MS; relapses; AEs and withdrawals; comorbidities; patient income; and the impact of these outcomes on resource use, costs, QoL, and mortality. This real-world evidence may be obtainable using structural treatment-monitoring systems and long-term registry data with sufficient data coverage and could enable the use of event-based or microsimulation methods in the assessments. In addition, IIA type analysis should be used to increase the clinical appeal of complex analyses.
CONCLUSIONS
Data presented from the present modeling study highlight the cost-effectiveness of teriflunomide 14 mg once daily compared with DMF 240 mg BID when the commonly cited threshold values are taken into account. In the present modeling study, teriflunomide 14 mg also dominated all other commonly used first-line DMTs for RRMS in Finland and was associated with the highest II. 
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E. Soini is a founding partner and employee of ESiOR Oy, Kuopio, Finland. ESiOR Oy carries out studies, statistical analysis, consultancy, education, reporting and health economic evaluations for several pharmaceutical, food industry, diagnostics and device companies; hospitals; consultancies; and academic institutions. J. Joutseno is employed by Genzyme, a Sanofi Company, Helsinki, Finland. M.-L. Sumelahti has been a consultant and member of advisory councils at Genzyme, Novartis, and Biogen, and has received a travel grant from Novartis. SUPPLEMENTARY MATERIAL Supplement A. EDSS-based RRMS and SPMS transition matrices EDSS 1 is the key outcome in the assessment of MS disability progression. In the Finnish PirkanmaaSeinäjoki-Vaasa MS registry, there were 1359 patients with MS with EDSS assessment data available, with altogether 2458 measurements. These patients were identified from administrative registries. The data collection, case ascertainment procedure, and ethical permits have been described in detail elsewhere. 2, 3 Incident MS cases diagnosed in the study region that fulfilled the McDonald 4 criteria were included. The classification of disease course to RRMS was performed using standardized definitions.
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A total of 1242 patients had RRMS, and these patients with RRMS had altogether 2299 EDSS measurements between August 27, 1986 , and December 31, 2010. Women accounted for 69.8% of the patients. In all, 62.2% of the EDSS assessments were carried out at the beginning of a DMT episode with an EDSS score of 0-7. In 2010, EDSS values were assessed for all patients alive (July 1, 2010, assumed, if no specific day shown in the data). Figure A .1 shows all EDSS measurements over time for descriptive purposes. As can be seen, most EDSS measurements were performed for patients with RRMS (green colored dots). The figure also shows that there was censoring in the EDSS measurements in EDSS classes 6.5-9.5.
EDSS Transitions in RRMS
For descriptive purposes, combined Figure A .2 shows the development from one EDSS measurement to the next among patients with RRMS, conditional on particular EDSS scores.
EDSS development over time needs to be modeled in order to estimate the progression of MS. MS progression for the model was estimated using integer RRMS EDSS scores (halves rounded up; 9.5 assumed to be 9.0 because the patient is alive when EDSS is 9.5). The JAGS software V3. When estimating the RRMS EDSS 0-9 transitions, uniform priors were assumed because no earlier Finnish transition probabilities data were available. Based on a prior knowledge of the data in question, 60% of the mortality was assumed to be MS-related. 7 This estimate was conservative in comparison to other estimates, which have a higher proportion of MSrelated mortality (eg, 78.3% in Goodin et al 8 ). The results shown in Table A .I are well in line with the recent British Columbia results. 9 
RRMS to SPMS Transition
The hazard rate (HR, λ) for conversion from RRMS EDSS 1 to SPMS was calculated assuming an exponential survival function (ie, a constant hazard of converting to SPMS over time):
SðtÞ¼expðÀλtÞ λ for an exponential distribution could be estimated from the median time of conversion to SPMS, reported to be 15 years based on London Ontario data, 10, 13 ie:
This gives an annual HR of 0.0462 for SPMSconversion of patients in EDSS 1.
The Finnish dataset includes only a few observations of conversion to SPMS, and an EDSS-specific rate could not be estimated from these. Based on the London Ontario data, the Cox proportional hazards model was: p ¼ 1ÀexpðÀrtÞ
EDSS Transitions in SPMS
For SPMS transitions, data from the London Ontario MS registry 10, 13 were available and used (Table A.III) , because the Finnish register data had too few EDSS measurements for patients with SPMS. Adverse events (AEs) were included to the modeling based on a Z4% difference between active treatment and placebo and/or clear inclusion in a previous NICE HTA submission (Table B .I). Nearly all AEs related to DMF, GA, interferons, and teriflunomide are mild to moderate and of short duration. The reason for not including the AEs with a o4% difference between placebo and active treatment and no NICE HTA reference was to simplify the analysis. Recently, the FDA added a progressive multifocal leukoencephalopathy (PML, a very severe AE) scenario to the DMF label. However, possible PML risk with DMF was ignored owing to uncertainty related to exact PML risk (usually PML risk accumulates over time).
In order to convert risk of AEs from studies to annualized risk of AEs, the risk of AEs was converted to a rate using a standard formula, 1 and the resulting annualized AE rates were then converted back to annualized probabilities/risks (Table B.I) . AEs were assumed to occur at most once per cycle. However, injection-site reaction, fever, and nausea tend to occur after every interferon dose, and chest pain, palpitation, and dyspnea may happen after every GA dose for subjects who have a particular AE. Consequently, the impact of those AEs may be underestimated for interferons and GA.
Treatment of AEs
In Finnish practice, the active treatment of severe AEs takes place in the neurology unit, and moderate AEs result in phone calls to the neurologic department. More severe AEs, including injection-site reactions, chest pain, palpitation, dyspnea, hot flush, and vomiting, require specialist consultation (Table B.II) . Chest pain and flushing, palpitation, and dyspnea related to GA are usually transient. 8 Asthenia, chills, diarrhea, flush, hair thinning, and nausea alone do not usually need active treatment; thus, phone contact to the neurologic department was assumed for these. Conservatively, 
Cost-Effectiveness Plane
Cost-Effectiveness Acceptability Frontier
Bayesian Treatment Ranking
According to Bayesian treatment ranking, teriflunomide was the best option, with a willingness-to-pay threshold of €0 (99.9%), €25,000 (100.0%), €37,000 (100.0%), €55,000 (96.2%), and €68,000 (75.2%) per QALY gained.
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